Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,570.65
(
-0.82%
)
US TECH 100
23,653.60
(
-0.60%
)
Dow Jones
45,770.04
(
-0.98%
)
Brent Oil
108.38
(
1.68%
)
Bitcoin
69,158.11
(
-2.92%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122798
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 199069

Thursday, 01/14/2016 7:55:18 PM

Thursday, January 14, 2016 7:55:18 PM

Post# of 257259
Re: ABBV’s Humira patents/AMGN-AGN FoB

Despite the unfavorable ruling in the IPR at the USPTO, AMGN/AGN still can—and probably will—launch its Humira FoB in the US market (pending FDA approval) and take its chances in court (#msg-118766059). Knocking out ABBV’s Humira patents via the IPR was Plan A… prevailing in a patent trial is Plan B. There’s also a possibility for a settlement.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now